ALISO VIEJO, Calif., July 14, 2015 /PRNewswire/ -- Sequent Medical announced today the grant by the U.S. Patent and Trademark Office of Patent No. 9,078,658, entitled “Filamentary Devices for Treatment of Vascular Defects.”
This new patent the eighth U.S. Patent granted to Sequent covers many versions of Sequent’s WEB Aneurysm Embolization System. WEB is a braided implant that includes composite drawn filled tube wires, i.e., an external nitinol tube and a highly radiopaque material disposed within the tube. Sequent’s WEB Aneurysm Embolization System devices utilize this technology for Enhanced Visualization (“EV”) while preserving desired mechanical properties. WEB is braided from numerous wires, which in some cases are less than one-quarter of the diameter of a human hair.
As previously reported, the company has developed and introduced in Europe EV versions of WEB in single-layer WEB SL and SLS configurations. In the United States, enrollment in an Investigational Device Exemption (“IDE”) clinical study called WEB-IT is underway; WEB EV designs are now being implanted in the study.
“We are pleased to have achieved this important milestone in our ongoing efforts to develop our intellectual property portfolio,” said Tom Wilder, President and Chief Executive Officer. “Improving the visualization of WEB proved to be a significant engineering challenge. EV technology is the latest demonstration of Sequent’s robust innovation capability, and further extends our leadership of the intrasaccular flow disruption category. The utility of Sequent’s proprietary technology extends beyond the neurovascular field, and has the potential to address a number of unmet clinical needs.”
About Sequent Medical, Inc.
Founded in 2007, Sequent Medical, Inc. (www.sequentmedical.com) is a privately held venture backed medical device company that is dedicated to the development of innovative catheter-based neurovascular technologies. WEB Aneurysm Embolization System and VIA® Microcatheter have both received the CE mark. The VIA has been cleared for commercial use in the United States. In the United States, WEB is an investigational device limited by United States law to investigational use. Sequent is headquartered in Aliso Viejo, California, and has European operations based in Bonn, Germany.
About WEBAneurysm Embolization System
Building upon the foundation of endovascular embolic coils, WEB is an intrasaccular flow disrupter that is implanted into a ruptured or unruptured intracranial aneurysm to promote rapid, peri-procedural stasis. WEB is based upon Sequent Medical’s proprietary MicroBraid technology, a dense mesh constructed from a large number of extremely fine wires. Unlike conventional medical braids, MicroBraid allows for a mix of wire diameters or materials to achieve a tailored balance of compliance, porosity and profile across device sizes.
WEB enables physicians to treat a broad range of intracranial aneurysms with the familiarity of an intrasaccular approach while using established biomaterials. To date, WEB has been used to treat over 1,700 ruptured and unruptured aneurysms worldwide.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sequent-medical-inc-awarded-us-patent-for-innovative-implant-designs-using-composite-wire-technology-300112314.html
SOURCE Sequent Medical, Inc.
Help employers find you! Check out all the jobs and post your resume.
